ArticleBMC public health2025
Overcoming challenges and achieving high HPV vaccination uptake in Cameroon: lessons learned from a gender-neutral and single-dose program and community engagement.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Understanding the roots of hesitancy to unlock the game-changing impact of HPV vaccination: Insights from a global qualitative evidence synthesis.Human vaccines & immunotherapeutics · 2026Review
- Financing of Human Papillomavirus Vaccination in Africa: A Scoping Review.Health science reports · 2026Review
- Elimination of HPV-associated cancers: universal HPV vaccination and the role of anal screening - a meeting report.BMC proceedings · 2026Article
- Perceptions of a gender-neutral approach to human papillomavirus (HPV) vaccination in Cameroon: a qualitative study.BMC public health · 2026Article
- Human Papillomavirus Vaccination Policies and Discourse on Social Media.JAMA health forum · 2026Article
- Assessing the impact of a gender-neutral approach to HPV vaccination on vaccination coverage for nine-year-old girls in Cameroon: A retrospective, cross-sectional study.PLOS global public health · 2026Article
- The vaccination status and attitudes toward human papillomavirus among gynecologists in China: A cross-sectional survey.Human vaccines & immunotherapeutics · 2025Article
- Stakeholders' perspectives on lessons learnt from HPV mass vaccination in Nigeria.BMC public health · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
introductionHuman papillomavirus (HPV) is sexually transmissible and affects almost all sexually active people. The virus infects females and males, causing genital warts, cervical cancer, and oropharyngeal cancers in some. The disease burden is highest in resource-constrained countries, and it is a leading cause of cancer-related mortality in Cameroon. HPV infection is preventable by vaccination. Despite the merits of HPV vaccination, improving coverage has remained difficult in Cameroon. This paper highlights the challenges, lessons learned, and progress in HPV vaccination as part of Cameroon's gender-neutral-single-dose approach and the periodic intensification of routine immunization (PIRI).
methodsThis ecological cross-sectional study, conducted from July to December 2023, examines the introduction of the HPV vaccine in Cameroon, along with associated challenges, strategies, and progress. Vaccination data from 2020 to 2023 were retrieved from Cameroon's District Health Information Software (DHIS2), while information on the vaccine introduction process and challenges was sourced from Expanded Programme on Immunisation (EPI) reports. Data analysis was performed using Python. The Shapiro-Wilk test assessed normality, and segmented regression analysis within an interrupted time series framework was applied to evaluate the contribution of each intervention to HPV vaccination uptake among girls. Statistical significance was set at a 95% confidence interval (CI) with a p-value < 0.05. Microsoft Excel 365 was used for calculating vaccination coverage proportions and visualizing results through figures and tables.
resultsCameroon introduced the HPV vaccine to nine-year-old girls in October 2020 amidst negative rumours. The first dose coverage stayed around 20% for three years. Following the National Immunization Technical Advisory Group recommendation, the Ministry of Health intensified communication and community engagement, switched to a single-dose vaccination for nine-year-old boys and girls in January 2023, and PIRI in households and schools in March 2023. All regions improved, with four (Adamawa, East, Far North, and North) having coverages for girls over 90% and around 40% for boys. National-level vaccination coverage for girls improved three-fold, and boys recorded 26%. Interrupted time series highlighted an immediate improvement in girls' vaccination following PIRI in 70% of regions and nationally. In contrast gender-neutral-single-dose vaccination led to immediate improvement in coverage in 30% of regions (Far North, South, South West) and at the national level, while intensified communication lacked significant contribution.
conclusionHPV vaccination in Cameroon has faced significant challenges. However, interventions such as adopting a gender-neutral, single-dose policy and implementing PIRI have greatly improved coverage across various levels of the health system since 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.